SPONSOR
Zhujiang Hospital
Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 1, Phase 2, Phase 4
Conditions studied: NSCLC Diagnosed by Histology or CytologyA Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical ResectionOverall Lung Function is Adequate for the Planned Lung ResectionAJCC is Classified as IB-IIICAcute LeukemiaArterial Aneurysm Wall Enhancement on HRMRIPreeclampsiaMicrobiomeBladder CancerStroke, Acute
Zhujiang Hospital is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IB-IIIC.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Zhujiang Hospital
How many clinical trials has Zhujiang Hospital sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Zhujiang Hospital, of which 9 are actively recruiting participants. These trials cover conditions including NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Zhujiang Hospital research focus on?
Zhujiang Hospital clinical trials span NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IB-IIIC, Acute Leukemia, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Zhujiang Hospital clinical trial?
To participate in a Zhujiang Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Zhujiang Hospital trials with current recruitment status updated daily.
Clinical Trials by Zhujiang Hospital
NCT07534033 Phase 2
Recruiting
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
NSCLC Diagnosed by Histology or Cytology
NCT07362095 Phase 1, Phase 2
Recruiting
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)
Acute Leukemia
NCT06539767
Recruiting
Risk Assessment and Mechanism Analysis of Intracranial Multiple Aneurysm Instability Based on High-resolution Magnetic Resonance, Imaging Histology and Hemodynamics
Arterial Aneurysm Wall Enhancement on HRMRI
NCT05445544
Recruiting
A Multicenter Cohort Study on Maternal and Infant Microecology and New Targets for Pre-eclampsia Screening in China
Preeclampsia
NCT05067101
Recruiting
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer
Bladder Cancer
NCT06418698
Recruiting
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy
Stroke, Acute
NCT06449833 Phase 4
Recruiting
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
Type2 Diabetes Mellitus
NCT06157060
Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Hepatocellular Carcinoma Resectable
NCT06215495
Recruiting
A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
Radiation Toxicity
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology